Sevoflurane and Percutaneous Coronary Intervention by Stent
Status:
Terminated
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can
represents a problem to the patients resulting in increase of morbidity and mortality.
Patients submitted of coronary angioplasty procedures can release in varying degrees of
creatine kinase, MB isoform (CK - MB), on the order of 30% of all angioplasty.
Possibly patients who will receive sevoflurane experience a higher level of cardiac cell
protection with lower incidence in the release of CK - MB values in excess of 100% baseline.